Definition
The FDA is the federal agency within the U.S. Department of Health and Human Services responsible for protecting public health by regulating the safety, efficacy, and security of human drugs, biological products, medical devices, food, cosmetics, and tobacco products.
Comprehensive Definition
The Food and Drug Administration (FDA) is one of the most consequential regulatory bodies in American healthcare. Established under the authority of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA oversees a vast portfolio of products that collectively account for roughly 20 cents of every dollar spent by American consumers. For healthcare operators, the FDA's reach touches nearly every clinical and business decision — from the drugs you prescribe and the devices you use, to the compounding pharmacy you partner with and the regenerative medicine products you offer.
The FDA is organized into several centers, each with jurisdiction over a specific product category. The Center for Drug Evaluation and Research (CDER) oversees prescription and over-the-counter drugs. The Center for Biologics Evaluation and Research (CBER) regulates vaccines, blood products, and certain cell and gene therapies. The Center for Devices and Radiological Health (CDRH) governs medical devices. The Center for Veterinary Medicine (CVM) handles animal drugs and food. Each center has its own review pathways, compliance standards, and enforcement mechanisms.
Drug approval at the FDA follows distinct pathways depending on the product type. A New Drug Application (NDA) is required for novel small-molecule drugs, while an Abbreviated New Drug Application (ANDA) is used for generic drugs seeking to demonstrate bioequivalence to an already-approved reference listed drug. Biologics — including monoclonal antibodies, vaccines, and blood-derived products — are approved via a Biologics License Application (BLA). Each pathway requires substantial clinical evidence, manufacturing data, and labeling review before a product may be marketed in the United States.
Medical device regulation operates on a risk-based classification system. Class I devices (e.g., bandages) are subject to general controls only. Class II devices (e.g., powered wheelchairs, certain diagnostic tests) typically require a 510(k) premarket notification demonstrating substantial equivalence to a legally marketed predicate device. Class III devices (e.g., implantable cardiac defibrillators) require a Premarket Approval (PMA) application, the most rigorous pathway, demanding valid scientific evidence of safety and effectiveness. The De Novo pathway provides a route for novel, low-to-moderate risk devices that lack a predicate.
Compounding pharmacies occupy a unique and often misunderstood space within FDA jurisdiction. Traditional patient-specific compounding by state-licensed pharmacies (503A pharmacies) is primarily regulated by state boards of pharmacy, but the FDA retains authority over the drugs used as ingredients and may act when compounded products present safety risks. Outsourcing facilities (503B pharmacies), created by the Drug Quality and Security Act of 2013, operate under direct FDA oversight and may produce larger batches without patient-specific prescriptions, subject to current Good Manufacturing Practice (cGMP) standards.
Regenerative medicine products — including platelet-rich plasma (PRP), exosomes, stromal vascular fraction (SVF), and certain stem cell therapies — are regulated under 21 CFR Part 1271 as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Products that are more than minimally manipulated or intended for non-homologous use are regulated as drugs or biologics and require FDA approval before clinical use. The FDA's enforcement discretion policy for certain regenerative medicine products expired in May 2021, meaning unapproved products that do not qualify for the HCT/P exemption are now subject to full enforcement.
Why It Matters
For healthcare operators — whether running a med spa, a functional medicine clinic, a telehealth platform, or a regenerative medicine practice — FDA compliance is not optional. Offering an unapproved drug, using a device outside its cleared indications, or partnering with a non-compliant compounding pharmacy can expose your practice to FDA warning letters, injunctions, seizures, and criminal prosecution. Beyond federal enforcement, FDA compliance failures create significant liability exposure in civil litigation and can trigger state medical board investigations.
Understanding the FDA's regulatory framework also creates competitive advantage. Operators who understand the difference between a 510(k)-cleared device and one that has received PMA approval can make better procurement decisions. Clinicians who understand the HCT/P framework can structure their regenerative medicine offerings to remain within the bounds of enforcement discretion — or make an informed decision to pursue an Investigational New Drug (IND) application for more aggressive protocols. In a market where many competitors operate in regulatory gray zones, demonstrated compliance is a differentiator that builds patient trust and protects long-term business value.
The FDA's regulatory posture is not static. Guidance documents, enforcement discretion policies, and warning letters signal shifting priorities. The agency's increased scrutiny of compounding pharmacies following the 2012 New England Compounding Center meningitis outbreak, its evolving framework for regenerative medicine, and its ongoing oversight of telehealth prescribing practices all illustrate how FDA policy directly shapes the operational landscape for modern healthcare businesses. Staying current with FDA guidance is not a compliance checkbox — it is a core business intelligence function.
Historical Background
The modern FDA traces its origins to the Pure Food and Drug Act of 1906, which prohibited the interstate commerce of adulterated or misbranded food and drugs. The agency's authority expanded dramatically after the 1937 sulfanilamide disaster, in which a poorly formulated antibiotic elixir killed over 100 people, prompting Congress to pass the Federal Food, Drug, and Cosmetic Act of 1938. This landmark legislation required pre-market safety review for new drugs for the first time.
The thalidomide crisis of the early 1960s — in which a sedative widely used in Europe caused severe birth defects — galvanized further reform. Although thalidomide was never approved in the United States largely due to the skepticism of FDA reviewer Frances Kelsey, the episode led to the Kefauver-Harris Drug Amendments of 1962, which added the requirement that drugs demonstrate efficacy in addition to safety before approval. The Medical Device Amendments of 1976 established the current device classification and premarket review system. The Drug Quality and Security Act of 2013 created the 503B outsourcing facility framework in direct response to the compounding pharmacy safety crisis. The 21st Century Cures Act of 2016 introduced the Regenerative Medicine Advanced Therapy (RMAT) designation and accelerated pathways for cell and gene therapies.
Federal Regulations
The FDA's primary statutory authority derives from the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) and the Public Health Service Act (42 U.S.C. § 201 et seq.). Key implementing regulations include:
21 CFR Part 314 — Applications for FDA Approval to Market a New Drug (NDA/ANDA requirements) 21 CFR Part 601 — Licensing of Biological Products (BLA requirements) 21 CFR Part 807 — Establishment Registration and Device Listing; Premarket Notification (510(k)) 21 CFR Part 814 — Premarket Approval of Medical Devices (PMA) 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P framework) 21 CFR Parts 210-211 — Current Good Manufacturing Practice for Finished Pharmaceuticals 21 CFR Part 503A — Pharmacy Compounding (traditional 503A pharmacies) 21 CFR Part 503B — Outsourcing Facilities (503B compounding)
The Drug Quality and Security Act (DQSA) of 2013 (Pub. L. 113-54) amended the FD&C Act to add Sections 503A and 503B, establishing the current compounding pharmacy regulatory framework. The 21st Century Cures Act (Pub. L. 114-255) added Section 3033 of the FD&C Act, creating the RMAT designation for regenerative medicine therapies.
State Considerations
While the FDA operates at the federal level, state law intersects with FDA regulation in important ways. State boards of pharmacy regulate 503A compounding pharmacies and may impose requirements that exceed or differ from FDA guidance. Some states have enacted their own compounding pharmacy laws that restrict the types of drugs that may be compounded or require additional patient-specific documentation.
For medical devices, states may impose additional registration or facility requirements beyond FDA clearance. California, for example, has its own device registration requirements administered by the California Department of Public Health. State medical practice acts govern how physicians may use FDA-approved and FDA-cleared products, including off-label use, which is legal under federal law but may be subject to state professional standards.
Regenerative medicine regulation varies significantly by state. Some states have enacted laws specifically addressing stem cell clinics and regenerative medicine advertising, while others rely entirely on the federal HCT/P framework. Operators should consult state-specific legal counsel in addition to understanding the federal FDA framework.
Common Mistakes
- Assuming FDA clearance (510(k)) is equivalent to FDA approval (PMA) — clearance means substantial equivalence to a predicate, not independent proof of safety and effectiveness.
- Partnering with a 503A compounding pharmacy for bulk, non-patient-specific orders — this is a 503B function and may expose the clinic to FDA enforcement.
- Offering exosomes, SVF, or other regenerative products without confirming they qualify for the HCT/P minimal manipulation / homologous use exemption under 21 CFR Part 1271.
- Using FDA-approved drugs in ways that constitute manufacturing (e.g., repackaging, relabeling, or combining) without the appropriate FDA registration.
- Failing to report adverse events involving medical devices through the MedWatch system, which is required for device user facilities under 21 CFR Part 803.
- Assuming that because a product is sold commercially it has been FDA-approved — many supplements, cosmetics, and "wellness" injectables are not FDA-approved drugs.
Operator Insight
In my work with healthcare operators across med spas, regenerative medicine clinics, and telehealth platforms, the most common FDA compliance gap I encounter is not willful disregard — it is a lack of structured regulatory intelligence. Operators often rely on vendor representations ("this product is FDA-compliant") without independently verifying the regulatory status of the products they use. That is a dangerous shortcut. Every product in your clinical workflow should have a documented regulatory status review: Is it an approved drug, a cleared device, or an HCT/P? Who is the registered manufacturer? What are the labeled indications, and are you using it within those indications? The second most common gap is compounding pharmacy due diligence. Many operators do not distinguish between 503A and 503B pharmacies, and they do not understand the implications of that distinction for their practice. If you are ordering compounded products in bulk — semaglutide, tirzepatide, peptides, hormone preparations — you need to understand whether your pharmacy is operating as a 503A or 503B facility, whether the drug is on the FDA's drug shortage list (which affects 503B bulk compounding eligibility), and whether your ordering practices are consistent with the applicable regulatory framework. My strong recommendation is to build a simple regulatory compliance checklist into your vendor onboarding process. For every new product or pharmacy partner, document the FDA registration number, the regulatory pathway (NDA, ANDA, BLA, 510(k), PMA, HCT/P exemption, or 503B registration), and the labeled indications. Review this documentation annually. This is not bureaucratic overhead — it is the foundation of a defensible compliance program.
— AJ Pakpour, Healthcare Practice Startup & Strategy Expert
In Practice
A functional medicine clinic in Texas wants to offer a regenerative medicine protocol using exosomes sourced from a commercial vendor. Before signing a supply agreement, the operator should verify whether the exosome product is registered as an HCT/P under 21 CFR Part 1271 and whether it qualifies for the minimal manipulation and homologous use exemptions. If the product is more than minimally manipulated or intended for systemic use beyond its homologous function, it is regulated as a drug or biologic and requires an approved BLA or an active IND. Operating without that approval exposes the clinic to FDA enforcement action, including a warning letter, injunction, and potential criminal referral. A telehealth platform seeking to offer compounded semaglutide to weight loss patients must navigate both the FDA's drug shortage framework and the 503B compounding rules. During a period when semaglutide is on the FDA's drug shortage list, 503B outsourcing facilities may compound semaglutide in bulk. Once the shortage is resolved, that authority ends. The platform's medical director must track FDA shortage list updates in real time and adjust prescribing protocols accordingly — a compliance function that requires active monitoring, not a one-time review.
Frequently Asked Questions
References
Further Reading
Turn Knowledge Into Action
Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.
Book a Strategy Session